These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10341866)

  • 1. Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment.
    Maugendre D; Gatel A; Campion L; Massart C; Guilhem I; Lorcy Y; Lescouarch J; Herry JY; Allannic H
    Clin Endocrinol (Oxf); 1999 Jan; 50(1):127-32. PubMed ID: 10341866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.
    Grebe SK; Feek CM; Ford HC; Fagerström JN; Cordwell DP; Delahunt JW; Toomath RJ
    Clin Endocrinol (Oxf); 1998 May; 48(5):585-92. PubMed ID: 9666870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.
    Edan G; Massart C; Hody B; Poirier JY; Lé Reun M; Hespel JP; Leclech G; Simon M
    BMJ; 1989 Feb; 298(6670):359-61. PubMed ID: 2564286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
    Mastorakos G; Doufas AG; Mantzos E; Mantzos J; Koutras DA
    J Endocrinol Invest; 2003 Oct; 26(10):979-84. PubMed ID: 14759070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
    Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
    Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal.
    Guilhem I; Massart C; Poirier JY; Maugendre D
    Thyroid; 2006 Oct; 16(10):1041-5. PubMed ID: 17042691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.
    García-Mayor RV; Páramo C; Luna Cano R; Pérez Mendez LF; Galofré JC; Andrade A
    J Endocrinol Invest; 1992 Dec; 15(11):815-20. PubMed ID: 1283984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.